133339-10-3

Basic information

• Product Name: 4-(3,5-Dinitrobenzoyl)morpholine
• Synonyms: 4-(3,5-Dinitrobenzoyl)morpholine;MFCD00426660;(3,5-dinitrophenyl)(morpholin-4-yl)methanone
• CAS NO: 133339-10-3
• Molecular Formula: C₁₁H₁₁N₃O₆
• Molecular Weight: 281.23
• Mol File: 133339-10-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3,5-Dinitrobenzoyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,5-Dinitrobenzoyl)morpholine(133339-10-3)
• EPA Substance Registry System: 4-(3,5-Dinitrobenzoyl)morpholine(133339-10-3)

Safety Data

• Hazardous Substances Data: 133339-10-3(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 99-34-3 3,5-dinitrobenzoic acid 
• 1523-21-3 4-nitrophenyl 3,5-dinitrobenzoate 
• 99-33-2 3,5-dinitrobenoyl chloride 

Downstream Products

• 503164-67-8 3-(morpholinomethyl)-5-nitroaniline 
• 313233-13-5 (3,5-diaminophenyl)(morpholin-4-yl)methanone 

Relevant articles and documents

Evidence for a catalytic six-membered cyclic transition state in aminolysis of 4-nitrophenyl 3,5-dinitrobenzoate in acetonitrile: Comparative Br?nsted-type plot, entropy of activation, and deuterium kinetic isotope effects

A kinetic study for reactions of 4-nitrophenyl 3,5-dinitrobenzoate (1a) with a series of cyclic secondary amines in acetonitrile is reported. Plots of the pseudo-firstorder rate constant (kobsd) vs [amine] curve upward, while those of kobs

2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof

The invention discloses 2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof. The structure of the 2-aminopyrimidine compounds is shown in the formula I, definitions of R1, R2, R3, R4, R5, X, Y, Z and W in the formula are shown in the specification and the claim. The compounds can effectively inhibit growths of a plurality of tumor cells, generate inhibition effects for EGFR and IGF1R protease, and is used for preparing antitumor drugs; the compounds can overcome drug resistance which is induced by prior medicaments Gefitinib and Erlotinib and the like, has selectivity for tumor, especially wild type non-small cell lung cancers, and has good pharmacokinetics property.